Alnylam Pharmaceuticals, Inc.
HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Last updated:

Abstract:

The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.

Status:
Application
Type:

Utility

Filling date:

17 Nov 2021

Issue date:

30 Jun 2022